NCT07356856

Brief Summary

In this study, microtransplantation (MST) will be administrated to patients diagnosed with advanced / relapsed solid tumors to assess the therapeutic efficacy and safety of conventional chemotherapy in combination with MST for the treatment of advanced/relapsed solid tumors.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for phase_1

Timeline
25mo left

Started Jan 2026

Typical duration for phase_1

Geographic Reach
1 country

3 active sites

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress13%
Jan 2026Jun 2028

First Submitted

Initial submission to the registry

January 13, 2026

Completed
2 days until next milestone

Study Start

First participant enrolled

January 15, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

January 21, 2026

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 16, 2028

Expected
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2028

Last Updated

January 21, 2026

Status Verified

January 1, 2026

Enrollment Period

2 years

First QC Date

January 13, 2026

Last Update Submit

January 13, 2026

Conditions

Advanced and Relapsed Solid Tumors

Keywords

microtransplantationsolid tumors

Outcome Measures

Primary Outcomes (2)

  • Treatment-Emergent Adverse Events

    Treatment related mortality

    1 month

  • time of hematopoietic recovery

    Absolute neutrophil count \>500/μL; Platelets ≥20,000/μL

    1 month

Secondary Outcomes (1)

  • Disease Control Rate, DCR

    1 year

Study Arms (1)

microtransplantation; MST

EXPERIMENTAL

conventional chemotherapy with microtransplantation

Biological: MST

Interventions

MSTBIOLOGICAL

conventional chemotherapy with microtransplantation(MST). Microtransplantation, which is the infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood mononuclear cells (GPBMC)

microtransplantation; MST

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients are 18 to 90 years old, regardless of gender or race;
  • Advanced / relapsed solid tumors (small cell lung cancer, ovarian cancer, cervical cancer, gastric and colorectal cancer, sarcoma, head and neck tumor, etc.) are confirmed by clinical or histopathological diagnosis;
  • More than two kinds of tumors are allowed;
  • Karnofsky score ≥ 40, ECoG physical status ≤ 3;
  • There are measurable lesions;

You may not qualify if:

  • The researchers considered patients who were not suitable to participate in this experiment；
  • Patients with mental disorders；
  • Patients who refuse to cooperate with the treatment；

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Innovvy(Beijing) Biomedical Technology Co., Ltd

Haidian, Beijing Municipality, China

Location

Minzu Hospital of Guangxi Zhuang Autonomous Region

Nanning, Guangxi, China

Location

The First People's Hospital of Nanning

Nanning, Guangxi, China

Location

Study Officials

  • Xiang Lu, Professor

    The First People's Hospital of Nanning

    PRINCIPAL INVESTIGATOR

  • huiqin Wei, Professor

    Minzu Hospital of Guangxi Zhuang Autonomous Region

    PRINCIPAL INVESTIGATOR

  • yajing Huang, Professor

    Innovvy(Beijing) Biomedical Technology Co., Ltd

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Xiang Lu, Professor

CONTACT

86-180771072962584779171@qq.com

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director

Study Record Dates

First Submitted

January 13, 2026

First Posted

January 21, 2026

Study Start

January 15, 2026

Primary Completion (Estimated)

January 16, 2028

Study Completion (Estimated)

June 1, 2028

Last Updated

January 21, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will not share

Locations

CN(3)